Min Yuen Teo - Concepedia

Author

Min Yuen Teo

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

M Y Teo, M. Teo, M. Y. Teo, M.Y. Teo, Min Y. Teo, Min Yuen Teo, Min-Yuen Teo, MinYuen Teo, Minh Yuen Teo, Minyuen Teo

222

Publications

4.5K

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Cornell University Molecular Oncology (United States)National Cancer Institute Tallaght University Hospital

About

Min Yuen Teo is an author at Memorial Sloan Kettering Cancer Center specializing in oncology, medicine, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	14	1.8K
2	Health Sciences	4	4	311
3	Immunology	4	4	346
4	Cell Biology	2	2	544
5	Genetic Medicine	1	1	16

Min Yuen Teo

Publications

3.4K

Citations

H-Index

Page 1

	Year	Citations
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients Bastien Nguyen, Christopher J. Fong, Anisha Luthra, Cell UrologyTumor HeterogeneityMedicineNext-generation SequencingPathology	2022	608
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers Min Yuen Teo, Kenneth Seier, Irina Ostrovnaya, Journal of Clinical Oncology Higher Response RatePathologyTumor BiologyPd-1/pd-l1 BlockadeGenitourinary Cancer	2018	528
DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma Min Yuen Teo, Richard Bambury, Emily C. Zabor, Clinical Cancer Research	2017	275
The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme Richard Bambury, Min Yuen Teo, D. Power, Journal of Neuro-Oncology Hematological MalignancyNeuro-oncologyRadiation OncologyLymphoid NeoplasiaOverall Survival	2013	216
Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer David Liu, Philip H. Abbosh, Daniel Keliher, Nature Communications	2017	156
Genomic Differences Between “Primary” and “Secondary” Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy Eugene J. Pietzak, Emily C. Zabor, Aditya Bagrodia, European Urology Surgical OncologyUrologyGenitourinary CancerMedicineDisparate Outcomes	2018	150
Cancer Susceptibility Mutations in Patients With Urothelial Malignancies Maria I. Carlo, Vignesh Ravichandran, Preethi Srinavasan, Journal of Clinical Oncology	2019	138
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma Andrea B. Apolo, Karla V. Ballman, Guru Sonpavde, New England Journal of Medicine	2024	125
Body Composition by Computed Tomography as a Predictor of Toxicity in Patients With Renal Cell Carcinoma Treated With Sunitinib S. Cushen, Derek G. Power, Min Yuen Teo, American Journal of Clinical Oncology	2014	97
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial Samuel A. Funt, Michael Lattanzi, Karissa Whiting, Journal of Clinical Oncology	2022	93

Page 1